117 related articles for article (PubMed ID: 20063426)
1. Irinotecan as maintenance therapy in high-risk hepatoblastoma.
Qayed M; Powell C; Morgan ER; Haugen M; Katzenstein HM
Pediatr Blood Cancer; 2010 May; 54(5):761-3. PubMed ID: 20063426
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic approaches in the treatment of children with hepatoblastoma.
Katzenstein HM; Rigsby C; Shaw PH; Mitchell TL; Haut PR; Kletzel M
J Pediatr Hematol Oncol; 2002 Dec; 24(9):751-5. PubMed ID: 12468918
[TBL] [Abstract][Full Text] [Related]
3. [Preliminary study on the efficacy of irinotecan in the treatment of childhood relapsed hepatoblastoma].
Chang J; Zhang YT; Zhong XD; Wang LZ
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jul; 15(7):588-90. PubMed ID: 23866285
[No Abstract] [Full Text] [Related]
4. Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan.
Ijichi O; Ishikawa S; Shinkoda Y; Tanabe T; Okamoto Y; Takamatsu H; Inomata Y; Kawano Y
Pediatr Transplant; 2006 Aug; 10(5):635-8. PubMed ID: 16857004
[TBL] [Abstract][Full Text] [Related]
5. Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11).
Palmer RD; Williams DM
Med Pediatr Oncol; 2003 Jul; 41(1):78-80. PubMed ID: 12764754
[No Abstract] [Full Text] [Related]
6. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).
Zsíros J; Brugières L; Brock P; Roebuck D; Maibach R; Child M; Morland B; Casanova M; Pariente D; Paris C; de Camargo B; Ronghe M; Zimmermann A; Plaschkes J; Czauderna P; Perilongo G
Eur J Cancer; 2012 Dec; 48(18):3456-64. PubMed ID: 22835780
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
O'Neill AF; Towbin AJ; Krailo MD; Xia C; Gao Y; McCarville MB; Meyers RL; McGahren ED; Tiao GM; Dunn SP; Langham MR; Weldon CB; Finegold MJ; Ranganathan S; Furman WL; Malogolowkin M; Rodriguez-Galindo C; Katzenstein HM
J Clin Oncol; 2017 Oct; 35(30):3465-3473. PubMed ID: 28892430
[TBL] [Abstract][Full Text] [Related]
8. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.
Katzenstein HM; Furman WL; Malogolowkin MH; Krailo MD; McCarville MB; Towbin AJ; Tiao GM; Finegold MJ; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Rodriguez-Galindo C; Meyers RL
Cancer; 2017 Jun; 123(12):2360-2367. PubMed ID: 28211941
[TBL] [Abstract][Full Text] [Related]
9. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
[TBL] [Abstract][Full Text] [Related]
10. Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma.
Natarajan E; Auerbach C; Cheron R; Pashankar F
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e659-e661. PubMed ID: 31259823
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies.
Trobaugh-Lotrario AD; Katzenstein HM
Pediatr Blood Cancer; 2012 Nov; 59(5):809-12. PubMed ID: 22648979
[TBL] [Abstract][Full Text] [Related]
12. Addition of Vincristine and Irinotecan to Standard Therapy in a Patient With Refractory High-risk Hepatoblastoma Achieving Long-term Relapse-free Survival.
Powers JM; Pacheco MM; Wickiser JE
J Pediatr Hematol Oncol; 2019 Apr; 41(3):e171-e173. PubMed ID: 29668545
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan as a maintenance therapy for hepatoblastoma: a comment.
Wiwanitkit V
J Cancer Res Ther; 2010; 6(4):588. PubMed ID: 21358112
[No Abstract] [Full Text] [Related]
14. Vincristine and irinotecan in children with relapsed hepatoblastoma: a single-institution experience.
Zhang YT; Feng LH; Zhong XD; Wang LZ; Chang J
Pediatr Hematol Oncol; 2015 Feb; 32(1):18-25. PubMed ID: 24852330
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
16. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
17. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study.
Katzenstein HM; London WB; Douglass EC; Reynolds M; Plaschkes J; Finegold MJ; Bowman LC
J Clin Oncol; 2002 Aug; 20(16):3438-44. PubMed ID: 12177104
[TBL] [Abstract][Full Text] [Related]
18. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
19. [Dysarthria during irinotecan administration].
Ceccaldi B; Kara F; Mommeja-Marin H; Bègue M; Saint Blancard P; Le Marec E; Hauteville D
Rev Med Interne; 2002 Nov; 23(11):950-1. PubMed ID: 12481397
[No Abstract] [Full Text] [Related]
20. Reducing irinotecan-associated diarrhea in children.
Wagner LM; Crews KR; Stewart CF; Rodriguez-Galindo C; McNall-Knapp RY; Albritton K; Pappo AS; Furman WL
Pediatr Blood Cancer; 2008 Feb; 50(2):201-7. PubMed ID: 17570704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
